Blood pressure surges during office-based transurethral microwave therapy for the prostate

Benjamin T. Larson, Lance A. Mynderse, Virend Somers, Michael R. Jaff, William P. Evans, Thayne R. Larson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: To investigate the occurrence of adverse blood pressure (BP) events during transurethral microwave therapy (TUMT) for benign prostatic hyperplasia. PATIENTS AND METHODS: We conducted a retrospective study of the vital signs of 185 consecutive patients who received TUMT (via 6 devices) at 4 institutions from March 1, 2003, to September 18, 2005. Maximum change, percent change in systolic BP, diastolic BP, mean arterial pressures, heart rate, and oxygen saturation were evaluated. RESULTS: Of the 185 patients, 77 patients (42%; 95% confidence interval [CI], 35%-49%) experienced an increase in systolic BP of more than 30 mm Hg during TUMT; 30 patients (16%; 95% CI, 12%-22%), an increase of more than 50 mm Hg; and 10 patients (5%; 95% CI, 3%-10%), an increase of more than 70 mm Hg. A greater than 20% change in systolic BP from baseline was observed in 95 patients (51%; 95% CI, 44%-58%). Many men experienced multiple events, with an average time of onset of 15.9 minutes into treatment. Significant differences were noted among the devices. CONCLUSION: This retrospective study demonstrates a significant number of BP surges during TUMT for benign prostatic hyperplasia. These BP changes represent a potential risk of cardiovascular events in patients with known or occult cardiovascular disease. Our study is the first to recognize the incidence of this BP response. Until further studies identify the mechanisms responsible for these surges in BP, the results of this study suggest that BP should be monitored, treatment adjusted, and antihypertensive medications continued during all TUMT.

Original languageEnglish (US)
Pages (from-to)309-312
Number of pages4
JournalMayo Clinic Proceedings
Volume83
Issue number3
DOIs
StatePublished - 2008

Fingerprint

Microwaves
Prostate
Blood Pressure
Therapeutics
Confidence Intervals
Prostatic Hyperplasia
Retrospective Studies
Equipment and Supplies
Vital Signs
Antihypertensive Agents
Arterial Pressure
Cardiovascular Diseases
Heart Rate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Blood pressure surges during office-based transurethral microwave therapy for the prostate. / Larson, Benjamin T.; Mynderse, Lance A.; Somers, Virend; Jaff, Michael R.; Evans, William P.; Larson, Thayne R.

In: Mayo Clinic Proceedings, Vol. 83, No. 3, 2008, p. 309-312.

Research output: Contribution to journalArticle

Larson, Benjamin T. ; Mynderse, Lance A. ; Somers, Virend ; Jaff, Michael R. ; Evans, William P. ; Larson, Thayne R. / Blood pressure surges during office-based transurethral microwave therapy for the prostate. In: Mayo Clinic Proceedings. 2008 ; Vol. 83, No. 3. pp. 309-312.
@article{0803fd56935b44bf941647b948b7afa4,
title = "Blood pressure surges during office-based transurethral microwave therapy for the prostate",
abstract = "OBJECTIVE: To investigate the occurrence of adverse blood pressure (BP) events during transurethral microwave therapy (TUMT) for benign prostatic hyperplasia. PATIENTS AND METHODS: We conducted a retrospective study of the vital signs of 185 consecutive patients who received TUMT (via 6 devices) at 4 institutions from March 1, 2003, to September 18, 2005. Maximum change, percent change in systolic BP, diastolic BP, mean arterial pressures, heart rate, and oxygen saturation were evaluated. RESULTS: Of the 185 patients, 77 patients (42{\%}; 95{\%} confidence interval [CI], 35{\%}-49{\%}) experienced an increase in systolic BP of more than 30 mm Hg during TUMT; 30 patients (16{\%}; 95{\%} CI, 12{\%}-22{\%}), an increase of more than 50 mm Hg; and 10 patients (5{\%}; 95{\%} CI, 3{\%}-10{\%}), an increase of more than 70 mm Hg. A greater than 20{\%} change in systolic BP from baseline was observed in 95 patients (51{\%}; 95{\%} CI, 44{\%}-58{\%}). Many men experienced multiple events, with an average time of onset of 15.9 minutes into treatment. Significant differences were noted among the devices. CONCLUSION: This retrospective study demonstrates a significant number of BP surges during TUMT for benign prostatic hyperplasia. These BP changes represent a potential risk of cardiovascular events in patients with known or occult cardiovascular disease. Our study is the first to recognize the incidence of this BP response. Until further studies identify the mechanisms responsible for these surges in BP, the results of this study suggest that BP should be monitored, treatment adjusted, and antihypertensive medications continued during all TUMT.",
author = "Larson, {Benjamin T.} and Mynderse, {Lance A.} and Virend Somers and Jaff, {Michael R.} and Evans, {William P.} and Larson, {Thayne R.}",
year = "2008",
doi = "10.4065/83.3.309",
language = "English (US)",
volume = "83",
pages = "309--312",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Blood pressure surges during office-based transurethral microwave therapy for the prostate

AU - Larson, Benjamin T.

AU - Mynderse, Lance A.

AU - Somers, Virend

AU - Jaff, Michael R.

AU - Evans, William P.

AU - Larson, Thayne R.

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: To investigate the occurrence of adverse blood pressure (BP) events during transurethral microwave therapy (TUMT) for benign prostatic hyperplasia. PATIENTS AND METHODS: We conducted a retrospective study of the vital signs of 185 consecutive patients who received TUMT (via 6 devices) at 4 institutions from March 1, 2003, to September 18, 2005. Maximum change, percent change in systolic BP, diastolic BP, mean arterial pressures, heart rate, and oxygen saturation were evaluated. RESULTS: Of the 185 patients, 77 patients (42%; 95% confidence interval [CI], 35%-49%) experienced an increase in systolic BP of more than 30 mm Hg during TUMT; 30 patients (16%; 95% CI, 12%-22%), an increase of more than 50 mm Hg; and 10 patients (5%; 95% CI, 3%-10%), an increase of more than 70 mm Hg. A greater than 20% change in systolic BP from baseline was observed in 95 patients (51%; 95% CI, 44%-58%). Many men experienced multiple events, with an average time of onset of 15.9 minutes into treatment. Significant differences were noted among the devices. CONCLUSION: This retrospective study demonstrates a significant number of BP surges during TUMT for benign prostatic hyperplasia. These BP changes represent a potential risk of cardiovascular events in patients with known or occult cardiovascular disease. Our study is the first to recognize the incidence of this BP response. Until further studies identify the mechanisms responsible for these surges in BP, the results of this study suggest that BP should be monitored, treatment adjusted, and antihypertensive medications continued during all TUMT.

AB - OBJECTIVE: To investigate the occurrence of adverse blood pressure (BP) events during transurethral microwave therapy (TUMT) for benign prostatic hyperplasia. PATIENTS AND METHODS: We conducted a retrospective study of the vital signs of 185 consecutive patients who received TUMT (via 6 devices) at 4 institutions from March 1, 2003, to September 18, 2005. Maximum change, percent change in systolic BP, diastolic BP, mean arterial pressures, heart rate, and oxygen saturation were evaluated. RESULTS: Of the 185 patients, 77 patients (42%; 95% confidence interval [CI], 35%-49%) experienced an increase in systolic BP of more than 30 mm Hg during TUMT; 30 patients (16%; 95% CI, 12%-22%), an increase of more than 50 mm Hg; and 10 patients (5%; 95% CI, 3%-10%), an increase of more than 70 mm Hg. A greater than 20% change in systolic BP from baseline was observed in 95 patients (51%; 95% CI, 44%-58%). Many men experienced multiple events, with an average time of onset of 15.9 minutes into treatment. Significant differences were noted among the devices. CONCLUSION: This retrospective study demonstrates a significant number of BP surges during TUMT for benign prostatic hyperplasia. These BP changes represent a potential risk of cardiovascular events in patients with known or occult cardiovascular disease. Our study is the first to recognize the incidence of this BP response. Until further studies identify the mechanisms responsible for these surges in BP, the results of this study suggest that BP should be monitored, treatment adjusted, and antihypertensive medications continued during all TUMT.

UR - http://www.scopus.com/inward/record.url?scp=41549105890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549105890&partnerID=8YFLogxK

U2 - 10.4065/83.3.309

DO - 10.4065/83.3.309

M3 - Article

C2 - 18315997

AN - SCOPUS:41549105890

VL - 83

SP - 309

EP - 312

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -